Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Streptococcus pneumoniae Challenge.

Chan WY, Entwisle C, Ercoli G, Ramos-Sevillano E, McIlgorm A, Cecchini P, Bailey C, Lam O, Whiting G, Green N, Goldblatt D, Wheeler JX, Brown JS.

Infect Immun. 2019 Feb 21;87(3). pii: e00846-18. doi: 10.1128/IAI.00846-18. Print 2019 Mar.

2.

Immunogenicity and mechanisms of action of PnuBioVax, a multi-antigen serotype-independent prophylactic vaccine against infection with Streptococcus pneumoniae.

Hill S, Entwisle C, Pang Y, Joachim M, McIlgorm A, Dalton K, Burbidge P, Colaco C, Brown J, Goldblatt D, Bailey C.

Vaccine. 2018 Jul 5;36(29):4255-4264. doi: 10.1016/j.vaccine.2018.05.122. Epub 2018 Jun 9.

PMID:
29895498
3.

Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial.

Entwisle C, Hill S, Pang Y, Joachim M, McIlgorm A, Colaco C, Goldblatt D, De Gorguette D'Argoeuves P, Bailey C.

Vaccine. 2017 Dec 18;35(51):7181-7186. doi: 10.1016/j.vaccine.2017.10.076. Epub 2017 Nov 10.

PMID:
29132988
4.

Heat shock protein complex vaccination induces protection against Helicobacter pylori without exogenous adjuvant.

Chionh YT, Arulmuruganar A, Venditti E, Ng GZ, Han JX, Entwisle C, Ang CS, Colaco CA, McNulty S, Sutton P.

Vaccine. 2014 Apr 25;32(20):2350-8. doi: 10.1016/j.vaccine.2014.02.051. Epub 2014 Mar 10.

PMID:
24625340
5.

An ultra scale-down characterization of low shear stress primary recovery stages to enhance selectivity of fusion protein recovery from its molecular variants.

Lau EC, Kong S, McNulty S, Entwisle C, McIlgorm A, Dalton KA, Hoare M.

Biotechnol Bioeng. 2013 Jul;110(7):1973-83. doi: 10.1002/bit.24865. Epub 2013 Mar 16.

PMID:
23436198
6.

Isolated gastric cryptosporidiosis in an immunocompetent patient.

Ramsay DB, Long SE, Ali MA, Entwisle C, Orenstein JM, Rossi C, Borum ML.

Dig Dis Sci. 2007 May;52(5):1364-6. Epub 2007 Mar 20. No abstract available.

PMID:
17372826
7.

Q: How often should patients with hepatitis C be screened for esophageal varices?

Entwisle C, Younossi ZM.

Cleve Clin J Med. 2006 Aug;73(8):758-9. No abstract available.

PMID:
16913200
8.
9.

Anti-tumour therapeutic efficacy of OX40L in murine tumour model.

Ali SA, Ahmad M, Lynam J, McLean CS, Entwisle C, Loudon P, Choolun E, McArdle SE, Li G, Mian S, Rees RC.

Vaccine. 2004 Sep 9;22(27-28):3585-94.

PMID:
15315837
10.

Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virus.

Lucas M, Tsitoura E, Montoya M, Laliotou B, Aslanoglou E, Kouvatsis V, Entwisle C, Miller J, Klenerman P, Hadziyannis A, Hadziyannis S, Borrow P, Mavromara P.

J Gen Virol. 2003 Mar;84(Pt 3):545-54.

PMID:
12604804
12.

Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo.

Morris A, Vetto JT, Ramstad T, Funatake CJ, Choolun E, Entwisle C, Weinberg AD.

Breast Cancer Res Treat. 2001 May;67(1):71-80.

PMID:
11518468
13.

Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer.

Kim SH, Carew JF, Kooby DA, Shields J, Entwisle C, Patel S, Shah JP, Fong Y.

Cancer Gene Ther. 2000 Sep;7(9):1279-85.

14.

Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.

Ali SA, McLean CS, Boursnell ME, Martin G, Holmes CL, Reeder S, Entwisle C, Blakeley DM, Shields JG, Todryk S, Vile R, Robins RA, Rees RC.

Cancer Res. 2000 Mar 15;60(6):1663-70.

15.

Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancer.

Boursnell ME, Entwisle C, Ali SA, Sivasubramaniam SD, Reeder S, McLean CS, Blakeley DM, Miller J, Hill S, Shields JG, Inglis SC, Rees RC.

Adv Exp Med Biol. 1998;451:379-84. No abstract available.

PMID:
10026900
16.

An efficient selection system for packaging herpes simplex virus amplicons.

Zhang X, O'Shea H, Entwisle C, Boursnell M, Efstathiou S, Inglis S.

J Gen Virol. 1998 Jan;79 ( Pt 1):125-31.

PMID:
9460933
17.

Construction and Use of Cell Lines Expressing HSV Genes.

Entwisle C.

Methods Mol Med. 1998;10:89-96. doi: 10.1385/0-89603-347-3:89.

PMID:
21374223
18.

A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.

Boursnell ME, Entwisle C, Blakeley D, Roberts C, Duncan IA, Chisholm SE, Martin GM, Jennings R, Ni ChallanaĆ­n D, Sobek I, Inglis SC, McLean CS.

J Infect Dis. 1997 Jan;175(1):16-25.

PMID:
8985191
19.

Purification and characterisation of recombinant murine interleukin-5 glycoprotein, from a Baculovirus expression system.

Mitchell DL, Young MA, Entwisle C, Davies AN, Cook RM, Dodd I.

Biochem Soc Trans. 1993 Nov;21(4):332S. No abstract available.

PMID:
8131918
20.

A recombinant, chimeric enzyme with a novel mechanism of action leading to greater potency and selectivity than tissue-type plasminogen activator.

Robinson JH, Browne MJ, Carey JE, Chamberlain PD, Chapman CG, Cronk DW, Dodd I, Entwisle C, Esmail AF, Kalindjian SB, et al.

Circulation. 1992 Aug;86(2):548-52.

PMID:
1638720
21.

A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain.

Browne MJ, Carey JE, Chapman CG, Tyrrell AW, Entwisle C, Lawrence GM, Reavy B, Dodd I, Esmail A, Robinson JH.

J Biol Chem. 1988 Feb 5;263(4):1599-602.

Supplemental Content

Loading ...
Support Center